Work

cGMP Signaaltransductie in Hypertrofische en Toxische Cardiomyopathie

Year: 2013
Type: dissertation
Abstract: Heart failure is a syndrome in which the heart can no longer provide sufficient blood flow to meet the body’s demands. This condition often follows a chronic ominous course, leading to severe incapacitation and compromised survival. In the past quarter century, much progress has been made in understanding the molecular and cellular processes that contributeto heart failure, which has led to a considerable change in the scope of available therapies. However, chronic heart failure remains a major cause of morbidity and mortality, with a continuously increasing worldwideprevalence. Thus, the development of novel treatments targeting the underlying pathological mechanisms are warranted to halt and reverse the devastating consequences of this disease.Growing evidence suggestsa cardioprotective role of cyclic guanosine 3',5'-monophosphate (cGMP) in the pathophysiology of the heart. In the experimental studies presented in this thesis, we observed elevated myocardial expression of phosphodiesterase 5 (PDE5), an enzyme catalysing cGMP breakdown, both in patients with severe aortic stenosis and in mice with thoracic aortic constriction-induced chronic left ventricular (LV) pressure overload. Intriguingly, we detected a strikingly similar PDE5 expression pattern in cardiac myocytes when human and murine hearts were subjected to pronounced hypertrophic stress resulting in marked adverse LV remodelling. Aggravated LVdysfunction and dilatation after chronic pressure overload in mice witha transgenic cardiac myocyte-specific PDE5 overexpression, suggests that increased PDE5 levels in cardiac myocytes contribute to deleterious LVremodelling in pressure overloaded hearts. These transgenic mice displayed a blunted myocardial cGMP response to chronic pressure overload, lower cardiac levels of the sarcoplasmic reticulum Ca2+-ATPase SERCA2, and elevated myocardial passive stiffness.In a second transgenic mouse model with reduced cGMP-synthesising soluble guanylate cyclase(sGC) activity in cardiac myocytes, doxorubicin-induced cardiotoxicity was exacerbated, as evidenced by greater LV dysfunction and dilatation. Transgenic hearts revealed increased lipid peroxidation and activation of the extrinsic apoptotic pathway after chronic doxorubicin treatment. A hypothesised increase in doxorubicin-induced mitochondrial dysfunction in these transgenic hearts is currently under investigation.Taken together, these data suggest that reduced cGMP bioavailability in cardiac myocytes represents a molecular hallmark heralding adverse LV remodelling and dysfunction during hypertrophic and toxic stress. Therefore, pharmacological modulation of cGMP signalling, via administration of PDE5 inhibitors or sGC stimulators/activators, may represent a promising therapeutic approach for various cardiac pathologies resulting in heart failure, including chronicpressure overload-induced LV remodelling and anthracycline-induced cardiotoxicity.
Source: Lirias
Language: English
Open Access status: green
OpenAlex ID: W7036696348
Cites: 333
Cited by:
Related to: 9